VPT:CC - Echocardiologists in Latin America Express Strong Interest in Ventripoint Whole Heart Analysis Products
(TheNewswire)
Toronto, Ontario – TheNewswire –August 10, 2022 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) participated in the 11 th CardiovascularImaging Conference (DIC) hosted by the Brazilian Society of Cardiology(SBC), 29-31 July 2022, in Sao Paulo, Brazil.
The SBC is Brazil’s top professional association with13,500 members in 26 regional societies throughout the country. TheDIC-SBC conference, co-sponsored by major ultrasound suppliers in theindustry, attracted participants from leading cardiovascular centers,research universities, private clinics and government.
Ventripoint’s podium presentation, “ A Rapid, Accurate and Reliable Technique to Analyze RVFunction in Echocardiograms from Patients with Congenital HeartDefects (CHD)”, attracted 75 CHD clinicians.The presentation featured use o f the company’s novel AI-basedtool ( VMS+3.0 ) to analyze standard 2Dechocardiograms to generate 3D model and cardiac measurements withaccuracy equivalent to MRI for the Right Ventricle (RV) and otherchambers of the heart . Dr. Gregory Skinner(Glenfield Hospital, UK) presented two case studies to showcase thebenefits of using VMS+3.0 for long-term follow-up of pediatricpatients with the CHD, Tetralogy of Fallot, following pulmonary valvereplacement. Dr. Skinner also commented he routinely takes theVMS+3.0 to the patients within the hospital and has successfullyanalyzed the heart of a 2.3-kilogram, premature baby in the neonatalICU. The presentation drew strong expressions of interest from leadingclinicians and institutions looking to adopt the system.
According to the DIC-SBC Conference Chairperson, Dr.Marly Uellendahl, “VMS+3.0 is an innovative technology thatgenerates three-dimensional data from two-dimensional echocardiogramdata and will have a major impact on clinical practice for sure,especially in evaluating the right ventricle."
"VMS+3.0 is the future of heart analytics and especially for CHD,” stated Dr. Adriana Mello, Vice-President of CongenitalEchocardiology at DIC-SBC.
The need for VMS+3.0 units to diagnose CHD in SouthAmerica is bigger than the United States. There are more childrenborn with CHD in South America than North America (65,000 in NorthAmerica and 71,000 in South America annually) and currently, there are2.2 million adults with congenital heart disease in the United States,with more than 1.8 million in South America. (1)
The Brazil healthcare market includes privatecompanies, HMOs and public institutions. The system features dedicatedcardiovascular centres and teaching hospitals that are world classsuch as Instituto do Coração (InCor USP), Hospital do Coração (HCor) and Instituto Dante Pazzanese de Cardiologia ( IDPC ) in Sao Paulo.
The Company has engaged a representative in Brazil andhe has initiated discussions with KOLs, distributors and regulatoryconsultants to establish a market entry plan and assess demand forVMS+ family of products in this rich region. The regulatory processin Brazil has recently been changed and it is estimated it will take 6to 12 months to complete depending on the classification theVMS+.
-
(1) John Jairo Araujo; “Adultswith Congenital Heart Disease in the Americas - Where we are today andwhere we are heading: A General View of the Inter-American Adult HeartDisease Council ( https://www.sciencerepository.org/adults-with-congenital-heart-disease-in-the-americas-where-we_JICOA-2020-3-102
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placedon the forward-looking statements and information because the Companycan give no assurance that they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2022 TheNewswire - All rights reserved.